Immunization with either prion protein fragment 95-123 or the fragment-specific antibodies rescue memory loss and neurodegenerative phenotype of neurons in olfactory bulbectomized mice

Neurobiology of Learning and Memory

Volumn 107, Issue , 2014, Pages 50-64

  Bobkova, N V ^a   Medvinskaya, N I ^a   Kamynina, A N ^d   Aleksandrova, I Y ^a   Nesterova, I V ^a   Samokhin, A V ^a   Koroev, D O ^d   Filatova, M P ^d   Nekrasov, P V ^a   Abramov, A Y ^e   Leonov, S V ^a,b,c   Volpina, O M ^d  

^a INSTITUTE OF CELL BIOPHYSICS   (Russian Federation)

^b Chemical Diversity Research Institute   (Russian Federation)

^c MOSCOW INSTITUTE OF PHYSICS AND TECHNOLOGY   (Russian Federation)

^d SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Amyloid; Antibody; Bulbectomy; Memory; Peptide; Prion

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[25-35]; PRION PROTEIN; PRION PROTEIN ANTIBODY; PRION PROTEIN[213-229]; PRION PROTEIN[95-123]; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN LEVEL; BRAIN NERVE CELL; BRAIN TISSUE; CENTRAL NERVOUS SYSTEM; CHOLINERGIC SYSTEM; CLINICAL FEATURE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HIPPOCAMPUS; IMMUNIZATION; IN VITRO STUDY; MALE; MEMORY DISORDER; MORRIS WATER MAZE TEST; MOUSE; NEUROPATHOLOGY; NEUROPROTECTION; NEWBORN; NONHUMAN; OLFACTORY BULBECTOMY; PROTEIN PURIFICATION; PROTEIN TARGETING; RAT; SEROTONINERGIC SYSTEM; SPATIAL MEMORY;

AMYLOID; ANTIBODY; BULBECTOMY; MEMORY; PEPTIDE; PRION;

AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODIES; HIPPOCAMPUS; IMMUNIZATION; IMMUNIZATION, PASSIVE; MALE; MAZE LEARNING; MEMORY DISORDERS; MICE; MICE, INBRED STRAINS; NERVE DEGENERATION; NEURONS; NEUROPROTECTIVE AGENTS; OLFACTORY BULB; PEPTIDE FRAGMENTS; PRIONS; PRPC PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; TEMPORAL LOBE;

EID: 84888799803     PISSN: 10747427     EISSN: 10959564     Source Type: Journal    
DOI: 10.1016/j.nlm.2013.10.019     Document Type: Article

References (77)

1. Abramov A.Y., Canevari L., Duchen M.R. Changes in intracellular calcium and glutathione in astrocytes as the primary mechanism of amyloid neurotoxicity. Journal of Neuroscience 2003, 23:5088-5095.
2. Aguzzi A., O'Connor T. Protein aggregation diseases: Pathogenicity and therapeutic perspectives. Nature Reviews Drug Discovery 2010, 9:237-248.
3. Aleksandrova I.Y., Kuvichkin V.V., Kashparov I.A., Medvinskaya N.I., Nesterova I.V., Lunin S.M., et al. Increased level of beta-amyloid in the brain of bulbectomized mice. Biochemistry (Moscow) 2004, 69:176-180.
4. Balducci C., Beeg M., Stravalaci M., Bastone A., Sclip A., Biasini E., et al. Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:2295-2300.
5. Banks W.A., Robinson W.A., Diaz-Espinoza S.M., Urayama R.A., Soto C. Transport of prion protein across the blood-brain barrier. Experimental Neurology 2009, 218:162-167.
6. Barry A.E., Klyubin I., Mc Donald J.M., Mably A.J., Farrell M.A., Scott M., et al. Alzheimer's disease brain-derived amyloid-β-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein. Journal of Neuroscience 2011, 31:7259-7263.
7. Bayer T.A., Schäfer S., Simons A., Kemmling A., Kamer T., Tepest R., et al. Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Abeta production in APP23 transgenic mice. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:14187-14192.
8. Bobkova N.V., Nesterova I.V., Dana R., Dana E., Nesterov V.I., Aleksandrova Y., et al. Morphofunctional changes in neurons in the temporal cortex of the brain in relation to spatial memory in bulbectomized mice after treatment with mineral ascorbates. Neuroscience and Behavioral Physiology 2004, 34:671-676.
9. Bobkova N.V., Nesterova I.V., Nesterov V.V. The state of cholinergic structures in forebrain of bulbectomized mice. Bulletin of Experimental Biology and Medicine 2001, 131:427-431.
10. Bobkova N., Vorobyov V., Medvinskaya N., Aleksandrova I., Nesterova I. Interhemispheric EEG differences in olfactory bulbectomized rats with different cognitive abilities and brain beta-amyloid levels. Brain Research 2008, 1232:185-194.
11. Calella A.M., Farinelli M., Nuvolone M., Mirante O., Moos R., Falsig J., et al. Prion protein and Abeta-related synaptic toxicity impairment. EMBO Molecular Medicine 2010, 2:306-314.
12. Caetano F.A., Beraldo F.H., Hajj G.N., Guimaraes A.L., Jürgensen S., Wasilewska-Sampaio A.P., et al. Amyloid-beta oligomers increase the localization of prion protein at the cell surface. Journal of Neurochemistry 2011, 117(3):538-553.
13. Chen S., Yadav S.P., Surewicz W.K. Interaction between human prion protein and amyloid-β (Aβ) oligomers: Role of N-terminal residues. The Journal of Biological Chemistry 2010, 285:26377-26383.
14. Chung E., Ji Y., Sun Y., Kascsak R.J., Kascsak R.B., Mehta P.D., et al. Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse. BMC Neuroscience 2010, 11:130.
15. Deane R., Zlokovic B.V. Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. Current Alzheimer Research 2007, 4:191-197.
16. Deli M.A., Sakaguchi S., Nakaoke R., Abraham C.S., Takahata H., Kopacek J., et al. PrP fragment 106-126 is toxic to cerebral endothelial cells expressing PrP(C). NeuroReport 2000, 11:3931-3936.
17. Desai V., Kaler S.G. Role of copper in human neurological disorders. The American Journal of Clinical Nutrition 2008, 88:855S-858S.
18. Fleminger S., Oliver D.L., Lovestone S., Rabe-Hesketh S., Giora A. Head injury as a risk factor for Alzheimer's disease; the evidence ten years on. A partial replication. Journal of Neurology, Neurosurgery & Psychiatry 2003, 74:857-862.
19. Forloni G., Angeretti N., Chiesa R., Monzani E., Salmona M., Bugiani O., et al. Neurotoxicity of a prion protein fragment. Nature 1993, 362:543-546.
20. Franz G., Beer R., Kampfl A., Engelhardt K., Schmutzhard E., Ulmer H., et al. Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury. Neurology 2003, 60:1457-1461.
21. Gimbel D.A., Nygaard H.B., Coffey E.E., Gunther E.C., Laurén J., Gimbel Z.A., et al. Memory impairment in transgenic Alzheimer mice requires cellular prion protein. The Journal of Neuroscience 2010, 30:6367-6374.
22. Giri R., Shen Y., Stins M., Du Yan S., Schmidt A.M., Stern D., et al. Beta-amyloid-induced migration of monocytes across human brain endothelial cells involves RAGE and PECAM-1. American Journal of Physiology 2000, 279:C1772-C1781.
23. Gunther E.C., Strittmatter S.M. Beta-amyloid oligomers and cellular prion protein in Alzheimer's disease. Journal of Molecular Medicine 2010, 88:331-338.
24. Guo Z., Cupples L.A., Kurz A., Auerbach S.H., Volicer L., Chui H., et al. Head injury and the risk of AD in the MIRAGE study. Neurology 2000, 54:1316-1323.
25. 2+/calmodulin kinase II and protein kinase C in mouse hippocampus. Journal of Pharmacology and Experimental Therapeutics 2008, 326:127-134.
26. Hardy J., Duff K., Hardy K.G., Perez-Tur J., Hutton M. Genetic dissection of Alzheimer's disease and related dementias: Amyloid and its relationship to tau. Journal of Pharmacology and Experimental Therapeutics 1998, 1:355-358.
27. Hartman R.E., Laurer H., Longhi L., Bales K.R., Paul S.M., McIntosh T.K., et al. Apolipoprotein E4 influences amyloid deposition but not cell loss after traumatic brain injury in a mouse model of Alzheimer's disease. The Journal of Neuroscience 2002, 22:10083-10087.
28. Hawkes C. Olfaction in neurodegenerative disorder. Movement Disorders 2003, 18:364-373.
29. Hozumi S., Nakagawasai O., Tan-No K., Niijima F., Yamadera F., Murata A., et al. Characteristics of changes in cholinergic function and impairment of learning and memory-related behavior induced by olfactory bulbectomy. Behavioural Brain Research 2003, 138:9-15.
30. Ikonomovic M.D., Uryu K., Abrahamson E.E., Ciallella J.R., Trojanowski J.Q., Lee V.M., et al. Alzheimer's pathology in human temporal cortex surgically excised after severe brain injury. Experimental Neurology 2004, 190:192-203.
31. Jeffrey M., Goodsir C.M., Race R.E., Chesebro B. Scrapie-specific neuronal lesions are independent of neuronal PrP expression. Annals of Neurology 2004, 55:781-792.
32. Johnson V.E., Stewart W., Smith D.H. Traumatic brain injury and amyloid-β pathology: A link to Alzheimer's disease?. Nature Reviews Neuroscience 2010, 11:361-370.
33. Kamynina A.V., Volpina O.M., Medvinskaya N.I., Aleksandrova I.Ju., Volkova T.D., Koroev D.O., et al. Vaccination with peptide 173-193 of acetylcholine receptor α7-subunit prevents memory loss in olfactory bulbectomized mice. Journal of Alzheimer's Disease 2010, 21:249-261.
34. Kovacs T. Mechanisms of olfactory dysfunction in aging and neurodegenerative disorders. Ageing Research Reviews 2004, 3:215-232.
35. Kovacs T., Cairns N.J., Lantos P.L. Olfactory centers in Alzheimer's disease: Olfactory bulb is involved in early Braak's stage. NeuroReport 2001, 12:285-288.
36. Lauren J., Gimbel D.A., Nygaard H.B., Gilbert J.W., Strittmatter S.M. Cellular prion protein mediates impairment of synaptic plasticity by amyloidbeta oligomers. Nature 2009, 457:1128-1132.
37. Le Pichon C.E., Firestein S. Expression and localization of the prion protein PrPC in the olfactory system of the mouse. Journal of Comparative Neurology 2008, 508:487-499.
38. Lee H.B., Lyketsos C.G. Depression in Alzheimer's disease: Heterogeneity and related issues. Biological Psychiatry 2003, 54:353-362.
39. Loane D.J., Pocivavsek A., Moussa C.E.H., Thompson R., Matsuoka Y., Faden A., et al. Amyloid precursor protein secretases as therapeutic targets for traumatic brain injury. Nature Medicine 2009, 15:377-379.
40. Luukinen H., Viramo P., Koski K., Laippala P., Kivela S.L. Head injuries and cognitive decline among older adults: A population-based study. Neurology 1999, 52:557.
41. Mallucci G.R., Ratté S., Asante E.A., Linehan J., Gowland I., Jefferys J.G., et al. Post-natal knockout of prion protein alters hippocampal CA1 properties, but does not result in neurodegeneration. The EMBO Journal 2002, 21:202-210.
42. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. Journal of Neuroscience Methods 1984, 11:47-60.
43. Mortimer J.A., French L.R., Hutton J.T., Schuman L.M. Head injury as a risk factor for Alzheimer's disease. Neurology 1985, 35:264.
44. Moser M., Colello R.J., Pott U., Oesch B. Developmental expression of the prion protein gene in glial cells. Neuron 1995, 14:509-517.
45. Nakajima A., Yamakuni T., Haraguchi M., Omae N., Song S.Y., Kato C., et al. Nobiletin, a citrus flavonoid that improves memory impairment, rescues bulbectomy-induced cholinergic neurodegeneration in mice. Journal of Pharmacological Sciences 2007, 105:122-126.
46. Nemetz P.N., Leibson C., Naessens J.M., Beard M., Kokmen E., Annegers J.F., et al. Traumatic brain injury and time to onset of Alzheimer's disease: A population-based study. American Journal of Epidemiology 1999, 149:32-40.
47. Nesterova I.V., Bobkova N.V., Medvinskaya N.I., Samokhin A.N., Aleksandrova I.Y. Morphofunctional state of neurons in the temporal cortex and hippocampus in relation to the level of spatial memory in rats after ablation of the olfactory bulbs. Neuroscience and Behavioral Physiology 2008, 38:349-353.
48. Nesterova I.V., Gurevich E.V., Nesterov V.I., Otmakhova N.A., Bobkova N.V. Bulbectomy-induced loss of raphe neurons is counteracted by antidepressant treatment. Progress in Neuro-Psychopharmacology & Biological Psychiatry 1997, 21:127-140.
49. Oboznaya M.B., Gilch S., Titova M.A., Koroev D.O., Volkova T.D., Volpina O.M., et al. Antibodies to a nonconjugated prion protein peptide 95-123 interfere with PrPSc propagation in prion-infected cells. Cellular and Molecular Neurobiology 2007, 27:271-284.
50. Ostrovskaya R.U., Gruden M.A., Bobkova N.A., Sewell R.D., Gudasheva T.A., Samokhin A.N., et al. The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer's disease model. Journal of Psychopharmacology 2007, 21:611-619.
51. Pankiewicz J., Prelli F., Sy M.S., Kascsak R.J., Kascsak R.B., Spinner D.S., et al. Clearance and prevention of prion infection in cell culture by anti-PrP antibodies. European Journal of Neuroscience 2006, 24:2635-2647.
52. Parkin E.T., Watt N.T., Hussain I., Eckman E.A., Eckman C.B., Manson J.C., et al. Cellular prion protein regulates beta-secretase cleavage of the Alzheimer's amyloid precursor protein. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:11062-11067.
53. Pentzek M., Grass-Kapanke B., Ihl R. Odor identification in Alzheimer's disease and depression. Aging Clinical and Experimental Research 2007, 19:255-258.
54. Peretz D., Williamson R.A., Kaneko K., Vergara J., Leclerc E., Schmitt-Ulms G., et al. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 2001, 412:739-743.
55. Picard-Hagen N., Gayrard V., Viguié C., Moudjou M., Imbs C., Toutain P.L. Prion protein in the cerebrospinal fluid of healthy and naturally scrapie-affected sheep. Journal of General Virology 2006, 87:3723-3727.
56. Plassman B.L., Havlik R.J., Steffens D.C., Helms M.J., Newman T.N., Drosdick D., et al. Documented head injury in early adulthood and risk of Alzheimer's disease and other dementias. Neurology 2000, 55:1158-1166.
57. Prinz M., Montrasio F., Furukawa H., van der Haar M.E., Schwarz P., Rulicke T., et al. Intrinsic resistance of oligodendrocytes to prion infection. The Journal of Neuroscience 2004, 24:5974-5981.
58. Rial D., Duarte F.S., Xikota J.C., Schmitz A.E., Dafré A.L., Figueiredo C.P., et al. Cellular prion protein modulates age-related behavioral and neurochemical alterations in mice. Neuroscience 2009, 164:896-907.
59. Roberts G.W., Gentleman S.M., Lynch A., Murray L., Landon M., Graham D.I. Beta amyloid protein deposition in the brain after severe head injury: Implications for the pathogenesis of Alzheimer's disease. Journal of Neurology, Neurosurgery & Psychiatry 1994, 57:419-425.
60. Roucou X., LeBlanc A.C. Cellular prion protein neuroprotective function: Implications in prion diseases. Journal of Molecular Medicine (Berlin) 2005, 83:3-11.
61. Rueber M., Al-Din A.S., Baborie A., Chakrabarty A. New variant Creutzfeldt-Jakob disease presenting with loss of taste and smell. Journal of Neurology, Neurosurgery & Psychiatry 2001, 71:412-418.
62. Sadowski M.J., Pankiewicz J., Prelli F., Scholtzova H., Spinner D.S., Kascsak R.B., et al. Anti-PrP Mab 6D11 suppresses PrPSc replication in prion infected myeloid precursor line FDC-P1/22L and in the lymphoreticular system in vivo. Neurobiology of Disease 2009, 34:267-278.
63. Salès N., Rodolfo K., Hässig R., Faucheux B., Di Giamberardino L., Moya K.L. Cellular prion protein localization in rodent and primate brain. European Journal of Neuroscience 1998, 10:2464-2471.
64. Schwarz A., Kratke O., Burwinkel M., Riemer C., Schultz J., Henkleinb P., et al. Immunization with a synthetic prion protein-derived peptide prolongs survival times of mice orally exposed to the scrapie agent. Neuroscience Letters 2003, 350:187-189.
65. Shyu W.C., Lin S.Z., Chiang M.F., Ding D.C., Li K.W., Chen S.F., et al. Overexpression of PrPC by adenovirus-mediated gene targeting reduces ischemic injury in a stroke rat model. The Journal of Neuroscience 2005, 25:8967-8977.
66. Smith C., Graham D.I., Murray L.S., Nicoll J.A. Tau immunohistochemistry in acute brain injury. Neuropathology and Applied Neurobiology 2003, 29:496-502.
67. Struble R.G., Dhanraj D.N., Mei Y., Wilson M., Wang R., Ramkumar V. Beta-amyloid precursor protein-like immunoreactivity is upregulated during olfactory nerve regeneration in adult rats. Brain Research 1998, 780:129-137.
68. Tran H.T., LaFerla F.M., Holtzman D.M., Brody D.L. Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-β accumulation and independently accelerates the development of tau abnormalities. The Journal of Neuroscience 2011, 31:9513-9525.
69. Udenfriend S., Meienhoferm J. The peptides: Analysis, synthesis and biology 1987, (p. 9), Academic Press, London.
70. Uryu K., Chen X.H., Martinez D., Browne K.D., Johnson V.E., Graham D.I., et al. Multiple proteins implicated in neurodegenerative diseases accumulate in axons after brain trauma in humans. Experimental Neurology 2007, 208:185-192.
71. Uryu K., Laurer H., McIntosh T., Praticò D., Martinez D., Leight S., et al. Repetitive mild brain trauma accelerates A beta deposition, lipid peroxidation, and cognitive impairment in a transgenic mouse model of Alzheimer amyloidosis. The Journal of Neuroscience 2002, 22:446-454.
72. Viegas P., Chaverot N., Enslen H., Perrière N., Couraud P.-O., Cazaubon S. Junctional expression of the prion protein PrPC by brain endothelial cells: A role in trans-endothelial migration of human monocytes. Journal of Cell Science 2006, 119:4634-4644.
73. Völkel D., Zimmermann K., Zerr I., Bodemer M., Lindner T., Turecek P.L., et al. Immunochemical determination of cellular prion protein in plasma from healthy subjects and patients with sporadic CJD or other neurologic diseases. Transfusion 2001, 41:441-448.
74. Warner M.D., Peabody C.A., Flattery J.J., Tinklenberg J.R. Olfactory deficits and Alzheimer's disease. Biological Psychiatry 1986, 2:116-118.
75. White A.R., Enever P., Tayebi M., Mushens R., Linehan J., Brandner S., et al. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 2003, 422:80-83.
76. Wisniewski T., Sigurdsson E.M. Murine models of Alzheimer's disease and their use in developing immunotherapies. Biochimica et Biophysica Acta - Molecular Basis of Disease 2010, 1802:847-859.
77. Yamamoto T., Jin J., Watanabe S. Characteristics of memory dysfunction in olfactory bulbectomized rats and the effects of cholinergic drugs. Behavioural Brain Research 1997, 83:57-62.